{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-010410","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.724336+00:00","generated_at":"2026-06-17T06:53:12.613188+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Neoleukin appoints interim CEO and CFO after Drachman resignation; CMO Patel departs","bullets":["Donna Cochener appointed Interim CEO; Sean Smith appointed Interim CFO, effective March 31, 2023.","Dr. Jonathan Drachman resigned as President, CEO and director, effective March 31, 2023 (previously announced March 6).","Cochener receives base salary $450,000; Smith $410,000; annual bonuses and retention bonuses up to $219,375 and $159,167 respectively.","CMO Dr. Priti Patel separated; receives 9 months salary continuation, healthcare, and accelerated vesting of 100,000 options.","Interim officers' severance: 9 months salary plus COBRA; enhanced 15 months lump sum on change of control."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-010410","json":"https://secwatch.observer/filing/0001628280-23-010410.json","markdown":"https://secwatch.observer/filing/0001628280-23-010410.md","text":"https://secwatch.observer/filing/0001628280-23-010410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000162828023010410/0001628280-23-010410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000162828023010410/nltx-20230403.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:53:12.613188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a936b1092","claim":"Donna M. Cochener was appointed as Interim Chief Executive Officer at Neurogene Inc..","evidence_excerpt":"the Board of Directors (the \"Board\") of Neoleukin Therapeutics, Inc. (the \"Company\") appointed (a) Donna M. Cochener as the Company’s Interim Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000162828023010410/0001628280-23-010410-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b8095c5d49","claim":"Jonathan Drachman resigned as President, Chief Executive Officer, principal executive and financial officer and director at Neurogene Inc..","evidence_excerpt":"Dr. Jonathan Drachman, M.D.'s resignation from his role as President, Chief Executive Officer, principal executive and financial officer and director of the Company as of the Effective Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000162828023010410/0001628280-23-010410-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President, Chief Executive Officer, principal executive and financial officer and director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}